Novartis’ CAR T therapy Kymriah nails main goal in follicular lymphoma
August 4, 2020Manufacturing and Production, Research and Development CAR-T therapy, Cancer, Kymriah, Novartis, car t therapy
Novartis is celebrating the success of its one-time CAR T therapy Kymriah (tisagenlecleucel) in patients with relapsed or refractory (r/r) …
FDA expands approval for Janssen’s Spravato nasal spray to cover major depressive disorder with suicidal ideation
August 4, 2020Manufacturing and Production FDA Janssen, Spravato, depression
The FDA has moved to expand the existing approval of Janssen’s Spravato (esketamine) CIII nasal spray to include treatment of symptoms …
CAR T cell therapy is revolutionising cancer treatment, but at what cost?
August 3, 2020Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing CAR T, CAR-T, Cancer, feature
CAR T cell therapy is one of the latest innovations in gene therapy. The process is primarily used to treat …
Novartis’ Cosentyx gets European go-ahead in paediatric plaque psoriasis
August 3, 2020Sales and Marketing Cosentyx, Europe, Novartis, pharma, psoriasis
Novartis’ interleukin-17A (IL-17A) inhibitor Cosentyx (secukinumab) has chalked up approval from the European Commission (EC) for the treatment of patients …
EU agrees deal with Sanofi for COVID-19 vaccine supply
August 3, 2020Sales and Marketing COVID, COVID-19, coronavirus
The EU has reached an agreement with Sanofi for 300 million doses of their COVID-19 vaccine candidate which will allow …
England to start using two new 90-minute COVID-19 tests in preparation for the winter
August 3, 2020Sales and Marketing COVID-19, coronavirus
Two new coronavirus tests are set to be made available throughout England that are significantly faster than most already in …
FDA gives nod for Monjuvi combo for second-line relapsed or refractory diffuse large B-cell lymphoma
August 3, 2020Sales and Marketing FDA, Incyte, Monjuvi, morphosys, pharma
The FDA has awarded MorphoSys and Incyte US approval for their Fc-modified cytolytic CD19-targeting monoclonal antibody Monjuvi (tafasitamab-cxix), when used …
FDA approves CBD treatment for seizures associated with tuberous sclerosis complex
August 3, 2020Sales and Marketing CBD, tsc
The FDA has approved Epidiolex (cannabidiol) as a treatment for seizures associated with tuberous sclerosis complex (TSC) in patients over …
US Government commits $2.1bn to GSK and Sanofi’s COVID-19 vaccine candidate
July 31, 2020Medical Communications, Research and Development COVID-19, GSK, Sanofi, US, Vaccine
The US Government has announced additional funding into Sanofi and GlaxSmithKline’s efforts to develop a recombinant protein-based vaccine to the …
Top Ten most popular articles on Pharmafile.com this week
July 31, 2020Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing COVID-19, Roche, UK government, Vaccine, lilly, pharma, top 10
Another week dominated by COVID-19. Among our most popular stories this week, Celltrion’s infliximab biosimilar Remsima has scored approval for …
Japan reserves 120m doses of BioNTech’s COVID-19 vaccine
July 31, 2020Manufacturing and Production, Medical Communications BioNTech, COVID-19, Japan, Vaccine, pharma
Japan’s Ministry of Health, Labour and Welfare (MHLW) has sealed a deal with Pfizer and BioNTech to secure 120 million …
FDA expands Stelara indication to cover paediatric plaque psoriasis
July 31, 2020Medical Communications, Sales and Marketing Janssen, Stelara, pharma, plaque psoriasis
Janssen’s IL-12 and IL-23 inhibitor Stelara (ustekinumab) has had its approved indications expanded by the FDA to include the treatment …
Bavencio+Inylta combo approved or Cancer Drugs Fund in advanced renal cell carcinoma
July 31, 2020Medical Communications, Sales and Marketing Merck, NICE, Pfizer, pharma
NICE has revealed that a combination of Merck KGaA’s Bavencio (avelumab) and Pfizer’s Inlyta (axitinib) will be made available as …
Lilly and Boehringer’s Jardiance reduces hospitalisation and CV death risk from heart failure at Phase 3
July 30, 2020Research and Development Boehringer, Eli Lilly, jardiance, pharma
Boehringer Ingelheim and Eli Lilly have announced strong Phase 3 news on their sodium-glucose co-transporter-2 (SGLT2) inhibitor Jardiance (empagliflozin) in …
Sanofi’s nirsevimab nails study goals for prevention of respiratory syncytial virus in infants
July 30, 2020Research and Development Sanofi, nirsevimab, pharma
Sanofi’s nirsevimab met its goals in a Phase 2b study, the company has revealed, investigating its efficacy in the prevention …
UCB syncs up with Roche and Genentech in Alzheimer’s drug deal worth a potential $2bn+
July 30, 2020Research and Development, Sales and Marketing Genentech, Roche, UCB, partnership
UCB Pharma is set to partner up with Roche and Genentech in a development and commercialisation deal focused on its …
BioNTech’s melanoma vaccine shows promise in early interim analysis
July 30, 2020Research and Development BioNTech, Cancer, pharma
While the company has more recently drawn headlines for its COVID-19 efforts, BioNTech has unveiled promising interim Phase 1 data …
NICE shoots down Kyowa Kirin’s Poteligeo for NHS treatment of mycosis fungoides or Sézary syndrome
July 30, 2020Sales and Marketing Kyowa Kirin, NICE, pharma
NICE has issued draft guidance that has shot down Kyowa Kirin’s therapy Poteligeo (mogamulizumab) for use on the NHS in …
Takeda poised to cut sales jobs in Japan as restructuring continues
July 29, 2020Medical Communications, Research and Development, Sales and Marketing Japan, Takeda, job cuts
Japan’s biggest drug firm Takeda is said to be mulling plans to cut back its sales operations with a new …
Pharmafile.com’s weekly COVID-19 news round-up
July 29, 2020Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing COVID-19, coronavirus, pharma
The once-touted COVID cure hydroxychloroquine continues its downward spiral of credibility as new data is published on its lack of …
Latest content
Major funding opportunity opens for early cancer diagnostics
Androlabs receives UK authorisation for new Testavan presentation
CEPI backs African-led Bundibugyo Ebola vaccine development
Cytomos appoints life sciences executive to board
